It has been reported that LSD1 inhibitor GSK287955 can repress proliferation of both AML and small-cell lung cancer (SCLC) cells in vitro and the growth of NCI-H1417 SCLC xenograft in vivo (18, 26). This evidence concerns the gene KDM1A and acute myeloid leukemia.